SVP Drug Discovery
Join our VP of Drug Discovery, Bryn Williams-Jones, at hubXchange’s European Hybrid AI in Drug Discovery Xchange 2021
HubXchange brings together executives from pharma and biotech to address and find solutions to the key issues faced in AI-led drug discovery. In this talk, Bryn Williams-Jones, VP Drug Discovery, will explore how he bridges the world’s of science and technology to help guide technologists in their work to develop AI tools that meet hyper-specific scientific requirements. He will then demonstrate how BenevolentAI applies these tools to empower target identification and precision medicine. Bryn will cite case studies from BenevolentAI’s work in novel target discovery, drug repurposing and in collaboration with AstraZeneca.
Bryn Williams-Jones is BenevolentAI’s Senior Vice President Drug Discovery and is responsible for driving the application of our AI-enabled drug discovery platform – the Benevolent Platform™ – to generate new target hypotheses for different diseases across the BenevolentAI portfolio. In this way, his role is key in bringing together our biology and AI capabilities.
Back to events